Managing antithrombotic regimens after carotid artery stenting represents a delicate clinical balancing act, especially in patients requiring long-term oral anticoagulation. Interventional neurologists, neurosurgeons, and cardiologists routinely encounter individuals with concurrent non-valvular atrial fibrillation or venous thromboembolism who undergo endovascular carotid revascularization. While traditional guidelines advocate dual antiplatelet therapy to prevent in-stent thrombosis, adding an anticoagulant creates triple therapy and drastically amplifies bleeding risks. Consequently, clinicians urgently need reliable evidence to guide antithrombotic de-escalation without compromising cerebrovascular protection.

The Clinical Dilemma of Anticoagulation in Carotid Artery Stenting

Carotid artery revascularization introduces acute thrombogenic surfaces that require immediate antiplatelet coverage. Historically, clinicians have relied on dual antiplatelet therapy, typically combining aspirin and clopidogrel, to mitigate perioperative thromboembolic risks. However, many patients presenting with carotid stenosis also live with comorbid cardiac arrhythmias, notably atrial fibrillation, which mandate oral anticoagulation for stroke prevention. Combining a direct oral anticoagulant with dual antiplatelet agents establishes a formidable triple antithrombotic regimen. Unfortunately, this intensive antithrombotic combination substantially elevates systemic and life-threatening bleeding complications. Therefore, neurointerventionalists frequently debate whether a direct oral anticoagulant plus single antiplatelet therapy offers adequate safety. While cardiology practice has largely abandoned prolonged triple therapy following coronary stenting, data regarding neurovascular stenting have remained sparse. As a result, practitioners must weigh the hazard of in-stent thrombosis against catastrophic intracranial hemorrhage when selecting post-procedural antithrombotic regimens.

Study Design and TriNetX Cohort Characteristics

To address this clinical uncertainty, investigators evaluated real-world patient records from the multicenter TriNetX Research Network. This expansive platform aggregates de-identified electronic health records from diverse healthcare organizations across the globe. Researchers identified adult patients aged 35 to 90 years who underwent endovascular carotid revascularization between January 2010 and January 2025. Specifically, the team compared patients receiving a direct oral anticoagulant paired with single antiplatelet therapy against those receiving a direct oral anticoagulant combined with dual antiplatelet therapy. Before adjustment, the initial query captured 1,973 eligible patients, including 304 individuals in the single antiplatelet cohort and 1,669 individuals in the dual antiplatelet group. To control for confounding indications, researchers executed a rigorous 1:1 propensity score matching protocol. Consequently, this matching strategy established two well-balanced cohorts containing 293 patients each, allowing a robust comparison of procedural outcomes across equivalent baseline profiles.

Hemorrhagic Outcomes and Procedural Safety Profiles

The primary safety outcome of the multicenter investigation focused specifically on the incidence of intracranial hemorrhage. Importantly, the analysis revealed no statistically significant difference between the two cohorts. Patients receiving a direct oral anticoagulant plus single antiplatelet therapy experienced an intracranial hemorrhage rate of 3.8%, whereas patients receiving dual antiplatelet therapy experienced a rate of 4.1%. This comparison yielded a risk ratio of 0.917 (95% CI, 0.411–2.044; P = .832), demonstrating clinical equivalence between both approaches. Furthermore, investigators tracked additional markers of secondary bleeding and healthcare burden. Gastrointestinal bleeding events showed no meaningful disparity between cohorts (P = .456). Similarly, emergency head imaging utilization remained entirely comparable across both patient groups (P = .931). Thus, dropping the second antiplatelet agent did not paradoxically increase symptomatic intracranial events or prompt additional diagnostic head scans during post-procedural monitoring.

Ischemic Protection and Long-Term Efficacy Metrics

Beyond hemorrhagic safety, clinicians must ensure that de-escalating antithrombotic therapy does not compromise ischemic neuroprotection. Fortunately, the secondary outcome metrics demonstrated excellent clinical parity between the evaluated regimens. New ischemic stroke occurred at comparable frequencies in both cohorts, showing no statistically significant divergence (P = .101). In addition, all-cause mortality rates remained similar between the single and dual antiplatelet groups (P = .520). The incidence of systemic venous thromboembolism, including pulmonary embolism and deep vein thrombosis, also did not differ significantly between arms (P = .261). Finally, inpatient hospital readmission rates remained statistically indistinguishable (P = .210). Therefore, eliminating aspirin from the post-procedural antithrombotic regimen did not expose patients to an excessive hazard of recurrent cerebral ischemia or systemic arterial embolization following successful stent deployment.

Translating Evidence to Routine Clinical Decision-Making

These findings provide reassuring observational evidence for clinicians navigating antithrombotic selection after carotid interventions. Because triple antithrombotic therapy carries substantial bleeding liability, choosing a direct oral anticoagulant plus a single antiplatelet agent represents a sensible strategy. In particular, patients with advanced age, previous gastrointestinal ulceration, severe renal disease, or elevated bleeding risk scores derive meaningful clinical reassurance from this regimen. Nonetheless, physicians must remember that retrospective database analyses carry inherent limitations, including residual unmeasured confounding. Clinicians should evaluate individual patient anatomy, plaque vulnerability, stent design, and procedural complexity prior to deciding on medication intensity. Ultimately, while awaiting confirmatory randomized controlled trials, treating teams can reasonably individualize antithrombotic intensity, utilizing dual antithrombotic therapy to balance cerebral perfusion against catastrophic bleeding.

Frequently Asked Questions

Why does combining a DOAC with dual antiplatelet therapy create significant safety concerns?

Combining direct oral anticoagulants with dual antiplatelet therapy establishes triple antithrombotic therapy, which drastically increases major bleeding risks. While antiplatelet agents prevent stent thrombosis, oral anticoagulants inhibit secondary fibrin generation. Simultaneous suppression of both pathways leaves vulnerable microvessels unprotected against hemorrhage. Consequently, eliminating aspirin substantially reduces catastrophic bleeding risks while preserving necessary antithrombotic efficacy through the combined action of a direct anticoagulant and a P2Y12 inhibitor.

Did the study observe higher ischemic stroke rates in patients receiving single antiplatelet therapy?

No, the study observed no statistically significant difference in ischemic stroke rates between cohorts. Patients receiving a direct oral anticoagulant plus single antiplatelet therapy experienced ischemic protection comparable to those on dual antiplatelet therapy. Furthermore, overall hospital readmissions, venous thromboembolic events, and all-cause mortality remained equivalent between groups. Therefore, omitting aspirin did not compromise overall stent patency or increase secondary thromboembolic recurrence during follow-up.

Which single antiplatelet agent do interventional teams typically choose alongside a DOAC?

Clinicians most frequently select a P2Y12 inhibitor, such as clopidogrel, when combining antiplatelet therapy with a direct oral anticoagulant. This preference aligns with extensive cardiovascular literature demonstrating that clopidogrel monotherapy combined with anticoagulation offers superior bleeding safety compared to aspirin-based regimens. However, physicians may substitute alternative agents or conduct platelet reactivity testing if patients harbor CYP2C19 loss-of-function alleles or exhibit documented clopidogrel resistance.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment and verify institutional protocols. Refer to the latest local and national guidelines for clinical practice.

References

Pekyi-Boateng PK et al. Direct Oral Anticoagulant Plus Single Versus Dual Antiplatelet Therapy After Carotid Artery Stenting: A Multicenter Propensity-Matched Cohort Study. Neurosurgery. 2026 Sep 22. doi: 10.1227/neu.0000000000004223. PMID: 42771008.

Pardo-Galiana B, et al. Antithrombotic Treatment after Carotid Stenting in Patients with Concomitant Atrial Fibrillation. American Journal of Neuroradiology. 2022;43(5):734-740.

Sfyroeras GS, et al. Antithrombotic Intensification After Carotid Artery Stenting in Patients with Atrial Fibrillation. Journal of Vascular Surgery. 2026;83(2):410-418.